Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer

NCT02718820 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Carcinoma

Interventions

DRUG: Docetaxel
DRUG: Pembrolizumab

Sponsor

Medical University of Vienna